menu search

KALA / Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment
Shares of Kala Pharmaceuticals Inc. KALA, +1.03% shot up 45.7% in premarket trading Wednesday, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational new drug (IND) application for KPI-012, its treatment of persistent corneal epithelial defect (PCED). With the acceptance, the company said late Tuesday that it is now turning its focus to clinical execution, and is looking to initiate a Phase 2 trial KPI-012 in the first quarter of 2023. Read More
Posted: Dec 28 2022, 06:48
Author Name: Market Watch
Views: 110690

KALA News  

KALA Up on Fast Track Designation to Lead Ocular Candidate

By Zacks Investment Research
April 13, 2023

KALA Up on Fast Track Designation to Lead Ocular Candidate

KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects. more_horizontal

Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know

By Zacks Investment Research
March 24, 2023

Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know

The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not prove more_horizontal

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

By GlobeNewsWire
March 8, 2023

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to more_horizontal

KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus

By Zacks Investment Research
March 6, 2023

KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus

Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6. more_horizontal

Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should Know

By Zacks Investment Research
February 22, 2023

Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should Know

Kala Pharmaceuticals (KALA) closed the most recent trading day at $11.90, making no change from the previous trading session. more_horizontal

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

By Seeking Alpha
January 19, 2023

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

FDA Accepted IND Filing for the company to initiate a phase 2b study using KPI-012 for the treatment of patients with the persistent corneal epithelia more_horizontal

Kala Pharmaceuticals Up 400% In The Past Month, What's Next?

By MarketBeat
January 11, 2023

Kala Pharmaceuticals Up 400% In The Past Month, What's Next?

Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom. more_horizontal

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

By Market Watch
December 30, 2022

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the bioph more_horizontal


Search within

Pages Search Results: